Literature DB >> 30312882

Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging.

Lisa K Koch1, Matthew M Yeh2.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and strongly associated with obesity, diabetes and the metabolic syndrome, not only in the Western societies, but also in most regions of the world in the 21st century. The spectrum of its histopathology ranges from steatosis to nonalcoholic steatohepatitis (NASH), with risk for progressive fibrosis that may lead to cirrhosis and hepatocellular carcinoma (HCC). Benign and malignant liver tumors have also been more frequently reported with the increasing prevalence of obesity and diabetes. This review addresses the pathology of NAFLD and NASH, and their diagnostic features, diagnostic pitfalls, grading and staging, and clinical correlation.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2018        PMID: 30312882     DOI: 10.1016/j.anndiagpath.2018.09.009

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  8 in total

1.  Neonatal Oral Administration of Chrysin Prevents Long-Term Development of Non-Alcoholic Fatty Liver Disease in a Sexually Dimorphic Manner in Fructose Nurtured Sprague Dawley Rats.

Authors:  Austin A Ajah; Busisani W Lembede; Pilani Nkomozepi; Kennedy H Erlwanger; Trevor T Nyakudya
Journal:  Life (Basel)       Date:  2022-05-26

2.  Berberine inhibits liver damage in rats with non-alcoholic fatty liver disease by regulating TLR4/MyD88/NF-κB pathway.

Authors:  Lingling Wang; Zhandong Jia; Bangcai Wang; Bin Zhang
Journal:  Turk J Gastroenterol       Date:  2020-12       Impact factor: 1.852

Review 3.  Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.

Authors:  Judith Aron-Wisnewsky; Chloé Vigliotti; Julia Witjes; Phuong Le; Adriaan G Holleboom; Joanne Verheij; Max Nieuwdorp; Karine Clément
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-03-09       Impact factor: 46.802

4.  Association Between Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome with Gallstone Disease, South Iran: A Population-Based Study.

Authors:  Masood Sepehrimanesh; Ramin Niknam; Fardad Ejtehadi; Mohammad Reza Fattahi; Alireza Safarpour
Journal:  Diabetes Metab Syndr Obes       Date:  2020-05-01       Impact factor: 3.168

Review 5.  Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH).

Authors:  Hannah K Drescher; Sabine Weiskirchen; Ralf Weiskirchen
Journal:  Cells       Date:  2019-08-07       Impact factor: 6.600

6.  Clinical and Metabolic Characteristics of Non-Alcoholic Fatty Liver Disease Patients in Saudi Arabia: Data from the Systematic Observatory Liver Disease (SOLID) Registry.

Authors:  Khalid Alswat; Faisal M Sanai; Waleed Al-Hamoudi; Mona Ismail; Yaser Dahlan; Hamdan Saleh AlGhamdi; Ibrahim Altraif; Abduljaleel Alalwan; Mohamed M A Babatin; Saleh A Alqahtani
Journal:  Diabetes Metab Syndr Obes       Date:  2021-03-16       Impact factor: 3.168

7.  A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity.

Authors:  Grit Zahn; Diana M Willmes; Nermeen N El-Agroudy; Christopher Yarnold; Richard Jarjes-Pike; Sabine Schaertl; Kay Schreiter; Wiebke Gehrmann; Andrea Kuan Cie Wong; Tommaso Zordan; Jörg König; Jens Jordan; Andreas L Birkenfeld
Journal:  Metabolites       Date:  2022-08-08

8.  Performance of Noninvasive Liver Fibrosis Tests in Morbidly Obese Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Saleh A Alqahtani; Pegah Golabi; James M Paik; Brian Lam; Amir H Moazez; Hazem A Elariny; Zachary Goodman; Zobair M Younossi
Journal:  Obes Surg       Date:  2021-02-22       Impact factor: 4.129

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.